3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Multiple Myeloma
34
Lymphoma, Non-Hodgkin
30
Leukemia, Myeloid, Acute
25
Hodgkin Disease
14
Precursor Cell Lymphoblastic Leukemia-Lymphoma
13
Myelodysplastic Syndromes
11
Lymphoma
10
Leukemia, Lymphocytic, Chronic, B-Cell
9
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
8
Leukemia
6
Neoplasms, Plasma Cell
5
Recurrence
3
Pancreatic Neoplasms
3
Lymphoma, Mantle-Cell
3
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma, Follicular
3
Hematologic Neoplasms
3
Gliosarcoma
3
Glioblastoma
3
Warts
2
Sezary Syndrome
2
Neutropenia
2
Myeloproliferative Disorders
2
Mycosis Fungoides
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, Large-Cell, Immunoblastic
2
Lymphoma, B-Cell, Marginal Zone
2
Leukemia, Hairy Cell
2
Infections
2
Immunologic Deficiency Syndromes
2
Interventions
Rituximab
12
Cyclophosphamide
12
fludarabine
8
dacetuzumab
7
blinatumomab
6
Tacrolimus
6
Busulfan
6
Vincristine
5
Prednisone
5
Etoposide
5
Doxorubicin
5
Bortezomib
5
fludarabine phosphate
4
Valganciclovir
4
Peripheral Blood Stem Cell Transplantation
4
Mycophenolic Acid
4
Epoetin Alfa
4
venetoclax
3
ibrutinib
3
Whole-Body Irradiation
3
Methotrexate
3
Melphalan
3
Lenalidomide
3
Ganciclovir
3
Everolimus
3
Dexamethasone
3
Darbepoetin alfa
3
Alemtuzumab
3
tetulomab tetraxetan lu-177
2
ponatinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Lymphoproliferative Disorders
×
plerixafor
×
Clear all
NCT01186224
2025-03-17
PHANTASTIC
University of Liverpool
Phase NA
Completed
60 enrolled